Retrospective and prospective studies in Asian and European patients with NSCLC have shown that the presence of EGFR mutations in exons 18–21 correlates with superior clinical outcome to EGFR tyrosine kinase inhibitors gefitanib and erlotinib [8], [9], [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.